Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.

Ellis, Lorie A; Malangone-Monaco, Elisabetta; Varker, Helen; Stetsovsky, Diana; Kubacki, Maureen; DeHoratius, Raphael J; Kafka, Shelly

Ellis, Lorie A; Malangone-Monaco, Elisabetta; Varker, Helen; Stetsovsky, Diana; Kubacki, Maureen; DeHoratius, Raphael J; Kafka, Shelly.

Afiliação

Ellis LA; Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Malangone-Monaco E; Life Sciences, IBM Watson Health, Armonk, NY, USA, emonaco@us.ibm.com.
Varker H; Life Sciences, IBM Watson Health, Cambridge, MA, USA.
Stetsovsky D; Life Sciences, IBM Watson Health, Cambridge, MA, USA.
Kubacki M; Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
DeHoratius RJ; Real World Value and Evidence, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Kafka S; Janssen Immunology, Medical Affairs, Sidney Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA, USA.

Clinicoecon Outcomes Res ; 11: 99-110, 2019.

Article em En | MEDLINE | ID: mdl-30679916